Glasgow_Prognostic_Score_GPS_for_Cancer_Outcomes_guideline v.1
Glasgow Prognostic Score (GPS) provides cancer prognosis based on serum biomarkers.
To provide cancer prognosis based on serum biomarkers, CRP, and Serum Albumin.
Use for patients with known cancer. Variables: CRP mg/L and Albumin g/dL or g/L. Formula: Selection of appropriate criteria. Interpretation: CRP ≤10 mg/L and Albumin ≥3.5 g/dL (35 g/L)= GPS 0 Good Prognosis CRP ≤10 mg/L and Albumin <3.5 g/dL (35 g/L) OR CRP >10 mg/L and Albumin ≥3.5 g/dL (35 g/L) = GPS 1 Intermediate Prognosis CRP >10 mg/L and Albumin <3.5 g/dL (35 g/L)= GPS 2 Poor Prognosis
1. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. British Journal of Cancer. 2003;89(6):1028-1030. doi:10.1038/sj.bjc.6601242. 2. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010 Jan;6(1):149-63. doi: 10.2217/fon.09.136. 3. Proctor MJ, Talwar D, Balmar SM, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. British Journal of Cancer. 2010;103(6):870-876. doi:10.1038/sj.bjc.6605855. 4. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. British Journal of Cancer. 2004;90(9):1704-1706. doi:10.1038/sj.bjc.6601789. 5. McMillan DC et. al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007 Aug;22(8):881-6. Epub 2007 Jan 24.
OBSERVATION.glasgow_prognostic_score_gps_for_cancer_outcomes.v0
